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Introduction to and Screening Visit Results of the Multicenter 
Pediatric Crohn’s Disease Growth Study
Neera Gupta, MD, MAS,* Robert H. Lustig, MD, MSL,† Howard Andrews, PhD,‡ Francisco Sylvester, MD,§  
David Keljo, MD, PhD,¶ Alka Goyal, MD,‖,  Ranjana Gokhale, MD,** Ashish S. Patel, MD,†† Stephen Guthery, 
MD,‡‡ and Cheng-Shiun Leu, PhD§§
Background: Statural growth impairment is more common in males with Crohn’s disease (CD). We assessed sex differences in height Z score 
differences and bone age (BA) Z scores and characterized age of menarche in a novel contemporary cohort of pediatric CD patients undergoing 
screening for enrollment in the multicenter longitudinal Growth Study.
Methods: Crohn’s disease patients (females with chronological age [CA] 5 years and older and younger than 14 years; males with CA 6 years 
and older and younger than 16 years) participated in a screening visit for the Growth Study. Height BA-Z scores are height Z scores calculated 
based on BA. Height CA-Z scores are height Z scores calculated based on CA. The height Z score difference equals height CA-Z score minus 
height BA-Z score.
Results: One hundred seventy-one patients (60% male) qualified for this analysis. Mean CA was 12.2 years. Mean height CA-Z score was −0.4, 
and mean height BA-Z score was 0.4 in females. Mean height CA-Z score was −0.1, and mean height BA-Z score was 0.2 in males. The absolute 
value of the mean height Z score difference was significantly greater in females (0.8) than males (0.3; P = 0.005). The mean BA-Z score in females 
(−1.0) was significantly lower than in males (−0.2; P = 0.002). The median CA at menarche was 13.6 (95% CI, 12.6–14.6) years.
Conclusions: Our screening visit data suggest that standardized height gain is lower in males with skeletal maturation and delayed puberty is 
common in females in CD. We are investigating these findings in the ongoing Growth Study.
Key Words:  inflammatory bowel disease, sex differences, height velocity, height
INTRODUCTION
Statural growth is a dynamic marker of overall health 
in children and adolescents. Statural growth impairment is 
both a marker of and complication of poorly controlled pe-
diatric Crohn’s disease (CD) in up to 80% of patients,1–16 more 
commonly in males.1–3, 5, 10, 11, 15, 17, 18 Understanding the etiology 
of these sex differences in growth impairment may help us to 
develop new targeted medical treatment strategies to improve 
height velocity and to optimize current treatments in high-risk 
patients.1, 19
Bone age (BA) assessed by left hand x-ray is regarded as a 
valid measure of skeletal maturity15, 20–23 and remaining growth 
potential. Determination of BA allows clinically meaningful 
interpretation of growth in the context of skeletal maturity in 
pediatric CD.24, 25 In our earlier single-center, cross-sectional 
study of pediatric CD patients, mean BA Z scores (BA results 
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standardized for sex and chronological age [CA]) (Table 1) were 
lower in females,24 raising the possibility of greater potential 
for catch-up growth once in remission in females and therefore 
less growth impairment in females. Chronological age at men-
arche was later in children with CD than healthy children,26 
supporting delayed puberty in females with CD27.
Determining the height Z score difference (height Z scores 
calculated based on CA [height CA-Z scores] minus height Z 
scores calculated based on BA [height BA-Z scores]; Table 1) 
allows assessment of standardized height gain in the context 
of skeletal maturation up to the date these measurements are 
obtained. Assessment of sex differences in height Z score differ-
ences will provide further insight into the potential etiology of 
sex differences in statural growth impairment in CD. Enrolling 
a sufficient number of patients to examine sex differences in 
growth impairment requires multicenter investigation in a novel 
contemporary cohort.
The Sex Differences in Statural Growth Impairment in 
Pediatric Crohn’s Disease study (also known as the Growth 
Study)28 is an ongoing prospective multicenter longitudinal co-
hort study designed to investigate the underlying mechanisms 
of sex differences in statural growth impairment in pediatric 
CD and to develop sex-specific prediction models to identify 
children at highest risk for developing growth impairment re-
fractory to standard therapeutic approaches. In this first report 
stemming from the Growth Study, our aims were to (1) assess 
sex differences in height Z score differences; (2) determine sex 
differences in BA Z scores; and (3) characterize the timing of 
menarche in a novel contemporary cohort of patients con-
senting/assenting to undergo screening for enrollment and par-
ticipation in the Growth Study.
METHODS
Two hundred three CD patients (females with CA 5 years 
and older and younger than 14 years; males with CA 6 years 
and older and younger than 16 years) participated in a screening 
visit at 1 of 8 medical centers between April 2015 and July 2019 
to determine eligibility for enrollment in the Growth Study 
(1 study visit every 6  months for a total of 5 study visits).28 
Chronological age criteria were established based on our prior 
cross-sectional study.1, 24, 26 Puberty is of longer duration in 
males, explaining the broader age range for eligibility criteria 
in males. During the screening visit, a patient was deemed eli-
gible to undergo a left hand x-ray for BA if  she or he met the 
following specific criteria, based on our prior cross-sectional 
study1, 24, 26: (1) CD diagnosed (newly or existing because we 
could adjust for disease duration in our multivariate analyses) 
by standard clinical, endoscopic, histologic and radiologic cri-
teria; (2) Tanner stage 1–4; (3) no standard of care BA result 
exceeding Growth Study eligibility criteria (standard of care 
BA older than 12 years for females or older than 14 years for 
males exceeds eligibility criteria in order to capture children 
with significant growth potential remaining, namely at least 3 
bone age years of statural growth potential remaining, allowing 
us to adequately study height velocity during the 2-year fol-
low-up period of the Growth Study28); (4) not having completed 
statural growth as clinically assessed by the standard of care 
pediatric gastroenterologist; (5) no liver disease; (6) no known 
cause of growth delay other than CD; (7) no other poorly con-
trolled medical conditions; (8) no history of pregnancy; (9) no 
history of treatment with growth hormone (GH), testosterone, 
or estrogen; and (10) available for 24 months of follow-up. If  a 
patient met these specific criteria and had not been exposed to 
corticosteroids (IV, oral, intranasal, inhaled, rectal, topical, eye 
drops, swish-and-spit/oral rinse, etc.) in the 56 days29 preceding 
the screening visit, a left hand x-ray for BA was obtained. If  
a patient met these criteria and had been exposed to cortico-
steroids, the patient was rescreened after 56  days of being 
corticosteroid free because recent use suppresses the growth 
hormone axis.
If  a patient was eligible for a left hand x-ray for BA 
based on these specific criteria, it was obtained as part of the 
screening visit. Bone age results determined whether a patient 
qualified for enrollment in the Growth Study. All x-rays were 
interpreted for BA by one of the investigators (RHL), using the 
standards of Greulich and Pyle,20 for data analyses.
Race was self-classified as white, black or African 
American, Asian, American Indian or Alaskan native, native 
Hawaiian or other Pacific islander, other, unknown or de-
clined. Asian was self-subclassified into South Asian or East 
Asian. Ethnicity was self-classified as Hispanic or Latino or not 
Hispanic or Latino. Tanner stage refers to breast development 
in females and testes/scrotum/penis development in males.
Chronological age and BA refer to the CA and BA of the 
patient at the screening visit. As BA reference values vary by sex 
and CA, BA results were transformed into BA Z scores using 
standard reference values.30 High BA was defined as BA Z score 
>2; low BA was defined as BA Z score <−2. Clinical informa-
tion was collected and self-Tanner staging was performed.31
Weight and height were measured using a digital scale to 
the nearest 0.1 kg and stadiometer to the nearest 0.1 cm, respec-
tively; body mass index (BMI) was calculated as the weight in 
kg divided by the square of the height in meters. The Z scores 
TABLE 1. Definitions of Variables
Variable Definition
BA Z score BA results standardized for sex and CA
Height CA-Z score Height Z score calculated based on CA
Height BA-Z score Height Z score calculated based on BA
Height Z score difference Height CA-Z score minus height BA-Z 
score
Absolute value of the  
Height Z score difference
The actual magnitude of the Height 
Z score difference without regard to 
its sign
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were calculated based on CA and BA for weight, height, and 
BMI (ie, weight, height, or BMI CA-Z score and weight, height, 
or BMI BA-Z score) using reference tables from the Centers for 
Disease Control and Prevention, National Center for Health 
Statistics.32 The height Z score difference was calculated as 
height CA-Z score minus height BA-Z score.
Statistical Analyses
Descriptive statistics were generated for participants’ 
demographic characteristics and key variables of interest. These 
variables were compared between males and females using the 
t test for continuous variables and χ 2 test for categorical vari-
ables. We employed linear regression to assess the sex difference 
for all outcomes. We also evaluated whether the sex difference 
was confounded by race, Tanner stage, or steroid exposure via 
multiple linear regression analyses. Race (white compared with 
non-white) and Tanner stage (Tanner stage 1 and 2 compared 
with Tanner stage 3 and 4)  were dichotomized due to small 
numbers in each category when left as multilevel categories. 
We reported the mean, standard deviation, and range for each 
outcome by sex and then the P values corresponding to the 
comparison between males and females; P values <0.05 were 
considered statistically significant. Kaplan-Meier curves were 
generated to show the cumulative incidence of menarche by CA 
and BA. The SIR/XS version 19 relational database manage-
ment system software was used to capture and store the data; 
CITRIX application-server was used to securely transmit the 
data to SIR/XS over the internet. Data were analyzed using 
SPSS Version 26.
Ethical Considerations
Each participating site obtained institutional review 
board approval for the study protocol, and written informed 
consent and assent were obtained from parents and patients be-
fore participation in the screening visit.
RESULTS
As of July 2019, 203 patients completed a screening visit. 
One hundred seventy-one patients (84%) qualified to obtain 
a BA and are included in this analysis. Table 2 shows demo-
graphic and Tanner stage information for these 171 patients 
(102 [60%] males). Race and ethnicity did not differ by sex 
(P = 0.867 and P = 0.686, respectively). One hundred sixty-
five (96.4%) participants were born in the United States, 1 was 
born (0.6%) in Canada, 2 were born (1.2%) in India, 1 was 
born (0.6%) in Mexico, 1 was born (0.6%) in Germany, and 1 
was born (0.6%) in South Africa. Tanner stage did not differ by 
sex (P = 0.845). The mean CA at screening visit for these pa-
tients was 12.2 ± 1.8 (SD; range, 7.3–15.9) years. The mean CA 
at screening visit for females was 11.6 ± 1.7 (range, 14.0–13.9] 
years and for males was 12.6 year ± 1.8 (range, 8.5–15.9) years 
(P < 0.001).
The mean height Z score difference was −0.3 ± 1.1 (SD; 
range, −3.9 to 2.0) in males and −0.8 ± 1.3 (−3.9 to 2.1) in fe-
males. The absolute value of the mean height Z score differ-
ence (Table 1) was significantly greater in females than males 
(P = 0.005; Fig.  1). The mean weight Z score difference was 
−0.2 ± 0.8 (range: −3.3 to 1.6) in males and −0.6 ± 0.9 (−3.2 
to 1.2) in females. The absolute value of the mean weight Z 
score difference was significantly greater in females than males 
(P = 0.003). The mean BMI Z score difference was −0.1 ± 0.3 
(−1.3 to 0.7) in males and −0.2 ± 0.4 (−1.1 to 0.5) in females. 
The absolute value of the mean BMI Z score difference was 
significantly greater in females than males (P = 0.008). Results 
did not change when adjusted for race, Tanner stage, or history 
of steroid exposure.
The mean BA at screening visit for all patients was 
11.6 ± 2.4 (SD; range, 6.0–17.0) years. The mean BA-Z score 
at screening visit for females (−1.0 ± 1.7; range, −5.4 to 2.5) 
was significantly lower than in males (−0.2 ± 1.6; range, −5.1 
to 4.0; P = 0.002). Seventeen (24.6%) females and 7 (6.9%) 
males (P = 0.001) had BA Z score <−2.0. 3 (4.3%) females and 
8 (7.8%) males (P = 0.528) had BA Z score >2.0. Results did 
not change when adjusted for race, Tanner stage, or history of 
steroid exposure.
Menarche had occurred in 16 (23.2%) of  69 females. 
Figure 2 shows the cumulative incidence of  menarche by CA. 
The median CA at menarche was 13.6 years (95% CI, 12.6 to 
14.6 years). Figure 3 shows the corresponding estimate of  the 
cumulative incidence of  menarche on the BA time scale for 
CD patients.
DISCUSSION
Analyses of  our data collected from a novel contempo-
rary cohort of  pediatric CD patients (females with CA 5 years 
and older and younger than 14 years; males with CA 6 years 
and older and younger than 16  years) participating in a 
screening visit for the Growth Study revealed that the abso-
lute value of  the mean height Z score difference was greater in 
females than males, indicating that standardized height gain 
is lower in males with BA progression (ie, skeletal maturation) 
up to the date of  the screening visit, reflecting poorer statural 
growth in males. Higher frequency of  growth impairment in 
males with CD has now been reported by several investiga-
tors.1–3, 5, 10, 11, 15, 17, 18 Though our data suggest that BA progres-
sion was intact in both males and females at the time of  the 
screening visit (ie, mean BA Z scores for each sex >−2), mean 
BA Z scores were lower in females, suggesting the possibility 
of  greater potential for catch-up growth and therefore less 
growth impairment in females. Fourteen percent of  all pa-
tients had BA Z scores <−2, which is 6 times what is expected 
(2.3%) for the general population. The frequency of  BA  Z 
scores <−2 was significantly greater in females. The median 
CA at menarche was older than reports in healthy females,26, 33 
supporting delayed puberty in females with CD, as in our 
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prior cross-sectional study.26 Bone age at the time of  menarche 
in CD is similar to that in previous reports of  healthy chil-
dren,34–36 as in our prior cross-sectional study.26
In our current report of pediatric CD patients, the me-
dian CA at menarche was 13.6 years, similar to our prior re-
port of 13.9  years.26 We previously reported the median CA 
of menarche in the 2007–2008 National Health and Nutrition 
Examination Survey (NHANES) cohort was 12.0  years,26 
similar to the 12.4  years reported in the third NHANES co-
hort.33 Delayed menarche is often seen in children with chronic 
TABLE 2. Demographics and Tanner Stage
N Percent
Sex   
Female 69 40.4%
Male 102 59.6%
Race   
Asian 8 4.7%
 East Asian 3  
 South Asian 5  
Black/African American 19 11.1%
Other 4 2.3%
White 139 81.3%
Declined 1 0.6%
Ethnicity   
Hispanic or Latino 6 3.5%
Not Hispanic or Latino 165 96.5%
   Males Females
Tanner Stage   N % N %
1 53 31.2% 30 29.4% 23 33.8%
2 45 26.5% 26 25.5% 19 27.9%
3 34 20.0% 22 21.6% 12 17.6%
4 38 22.3% 24 23.5% 14 20.6%
FIGURE 1. Mean height CA-Z score was −0.4 ± 1.0 (standard deviation), 
and mean height BA-Z score was 0.4 ± 1.2 in females. Mean height 
CA-Z score was −0.1 ± 1.0, and mean height BA-Z score was 0.2 ± 0.9 
in males. The slope of each regression line represents the mean height 
z score difference. The significantly steeper slope for females (solid 
regression line) than that for males (dashed regression line) indicates a 
significantly greater mean height Z score difference in females than in 
males (P = 0.005).
FIGURE 2. Cumulative incidence of menarche in females by chronolog-
ical age (years). The Kaplan-Meier survival curve shows the cumulative 
incidence of menarche at CA 11, 12, 13, and 14 years was 7.6% (95% 
CI, 0.3–14.5%), 18.0% (6.4–29.6%), 43.6% (24.4–62.8%), and 100% in 
female pediatric Crohn’s disease patients participating in a screening 
visit (N = 69).
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inflammatory conditions, such as juvenile idiopathic arthritis, 
systemic lupus erythematosus, and cystic fibrosis.37 Bone age at 
menarche has been reported as 13.0 years,35 13.1 years,36 and 
13.5  years34 in healthy children, similar to BA at the time of 
menarche in CD in this cohort and in the cohort in our prior 
cross-sectional study.26
Considering the varying definitions of growth impair-
ment used in different studies, taken together, the existing litera-
ture suggests that the frequency of statural growth impairment 
in pediatric CD has not changed in over 25  years,1–16 despite 
the introduction of several new biologic therapeutic agents 
to the IBD armamentarium. Because treatment strategies for 
improving growth impairment and final adult height in CD re-
main suboptimal,3, 8 a better understanding of the underlying 
mechanisms of growth impairment is required.
We are using the male-female dichotomy in risk for 
growth impairment in CD as a window for understanding the 
effects of inflammation on growth in both sexes.28 Sex is an im-
portant biological variable. Studying sex differences in growth 
impairment in CD will contribute to a deeper useful under-
standing of mechanisms of growth impairment and thus lead 
to the development of new targeted medical treatment strat-
egies to improve height velocity and final adult height and to 
optimize current treatments in high-risk patients in both sexes.
The impact of CD on growth is mediated by many fac-
tors including inflammation, genetics, nutrition, and medica-
tions. The defining hallmark of CD is inflammation. Growth 
impairment may be associated with ongoing intestinal inflam-
mation, even in the absence of intestinal symptoms. Insulin-like 
growth factor-1 (IGF-1) is the primary mediator of GH’s ef-
fects on statural growth, and sex steroids have a direct effect on 
the pubertal growth spurt. In our prior single-center, cross-sec-
tional study,1 we found that IGF-1 Z scores were lower in males. 
Nonspecific inflammatory markers such as erythrocyte sedi-
mentation rate (ESR), C-reactive protein (CRP), and albumin 
levels predicted IGF-1 Z scores but did not differ by sex, and 
were associated with testosterone and luteinizing hormone Z 
scores in males but not with estradiol and follicle stimulating 
hormone Z scores in females. These results suggest that the in-
flammation characteristic of CD has worse effects on hormone 
levels in males and that these negative inflammatory effects may 
explain the increased susceptibility to growth impairment in 
males. However, the specific underlying mechanisms of this sex 
difference in risk for growth impairment in CD remains poorly 
understood. We are investigating these intriguing single-center, 
cross-sectional findings and the findings from the screening 
visit of the Growth Study reported in this article in the ongoing 
prospective multicenter longitudinal Growth Study.
For patients qualifying for enrollment in the prospective 
multicenter longitudinal Growth Study28 based on screening 
visit BA results (ie, BA results that show potential for signif-
icant growth in stature remaining), we are obtaining serial 
measurements of growth and BA, allowing us to examine 
standardized height velocity and standardized BA progression. 
We will clarify determinants of BA and patterns of BA ad-
vancement by sex in this prospective longitudinal study. We are 
collecting serial measurements of inflammatory markers and 
hormone levels, nutrient intake assessments, and clinically im-
portant variables. We will determine sex differences in the im-
pact of inflammation on the hypothalamic-pituitary-gonadal 
axis, the growth hormone/IGF-1 axis, and height velocity. We 
will identify factors that classify a patient as high risk for devel-
oping growth impairment refractory to standard approaches to 
therapy. These patients may benefit from early introduction of 
aggressive medical therapies.
SUMMARY AND CONCLUSIONS
Our screening visit data suggest that standardized height 
gain is lower in males than females with skeletal maturation, 
supporting more frequent growth impairment in males. The 
higher frequency of growth impairment in males seems to be 
due to this lower standardized height gain with BA progression 
rather than advanced BA progression. In addition, our data 
support that delayed puberty is common in females with CD. 
The persistence of a sex difference in growth impairment in a 
novel contemporary cohort, despite the introduction of new 
treatment agents since the publication of earlier studies, sug-
gests that in the future our approach to treatment will likely be 
sex-specific.
We are investigating these initial findings in the on-
going prospective multicenter longitudinal Growth Study.28 
Addressing these critical gaps in our understanding of the 
underlying mechanisms of sex differences in growth impair-
ment in CD will have significant implications for the clinical 
management of these patients. Determining the specific path-
ways affected by inflammation in CD will allow us to identify 
targeted medical treatment strategies requiring further study. 
Developing sex-specific prediction models to identify patients 
FIGURE 3. Cumulative incidence of menarche in females by bone age 
(years). The Kaplan-Meier survival curve shows the cumulative inci-
dence of menarche based on BA in female pediatric Crohn’s disease 
patients participating in a screening visit (N = 69). The probability 
of menarche was 68% at BA 14.0 years and increased to 100% at BA 
greater than 15.0 years.
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at highest risk for growth impairment refractory to standard 
therapeutic approaches will identify candidates for appropriate 
early aggressive therapy. Multicenter prospective longitudinal 
collaborations are required to advance our science and there-
fore the care of our patients.
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